Effects of Antibody on Viral Kinetics in Simian/Human Immunodeficiency Virus Infection: Implications for Vaccination

Department of Haematology, Prince of Wales Hospital and Centre for Vascular Research, University of New South Wales, Kensington, New South Wales 2052, Australia.
Journal of Virology (Impact Factor: 4.65). 06/2004; 78(10):5520-2. DOI: 10.1128/JVI.78.10.5520-5522.2004
Source: PubMed

ABSTRACT Passive antibody treatment of macaques prior to simian/human immunodeficiency virus infection produces "sterilizing immunity" in some animals and long-term reductions in viral loads in others. Analysis of viral kinetics suggests that antibody mediates sterilizing immunity by its effects on the initial viral inoculum. By contrast, reduction in peak viral load later in infection prevents CD4 depletion and contributes to long-term viral control.

Download full-text


Available from: Lei Zhang, Aug 18, 2015
1 Follower
  • Source
    • "Understanding how these molecules function in vivo is important for designing vaccines and treatments based on broadly neutralizing antibodies. For example, quantitative analysis of data on passive immunization of macaques with 2G12 and 2F5 prior to viral challenge [5] [6] [7] suggested that the administration of antibodies could decrease the numbers of cells initially infected and modulate the long-term progress of the disease by limiting the depletion of CD4+ T cells [7]. However, Trkola et al. [3] subsequently studied whether passive immunization with these antibodies reduced the viral load in humans infected with HIV-1, after cessation of antiretroviral treatment (ART). "
    [Show abstract] [Hide abstract]
    ABSTRACT: We propose a mathematical model to interpret observations concerning the behavior of broadly neutralizing antibodies for chronic HIV in vivo. The model enables us to identify a threshold antibody level that must be achieved to decrease the viral load effectively. Although this threshold has not been reached in existing passive immunization studies, it is within range of humoral immune responses, suggesting that therapeutic vaccines are feasible. In an appendix, we develop a model of passive immunization against influenza, and acute infection.
    Vaccine 11/2011; 30(3):607-13. DOI:10.1016/j.vaccine.2011.11.048 · 3.49 Impact Factor
  • Source
    • "Passive transfer of human neutralizing antibodies can protect monkeys against intravenous or intravaginal SHIV89.6p challenge [34] by reducing the number of initially infected cells [35]. However, once HIV-1 infection is established, antibodies control HIV-1 replication only slightly [36], and escape mutants are rapidly selected [37]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Live attenuated measles vaccine (MV) could provide a safe and efficient pediatric vaccination vector to immunize children simultaneously against measles and human immunodeficiency virus type 1 (HIV-1). To evaluate the capacity of a vector derived from the certified Schwarz measles vaccine (MVSchw) to prime effective cytotoxic T cells (CTL) and broad neutralizing antibodies against HIV-1 conserved epitopes, we generated recombinant MVSchw viruses expressing HIV-1 antigens. We demonstrate that a recombinant MVSchw virus expressing an HIV-1-derived CTL polyepitope primes effective HLA-A0201-restricted CTLs against multiple conserved HIV-1 epitopes in mice susceptible to measles and humanized for the major histocompatibility complex (MHC) class-I molecule HLA-A0201. Additionally, we show that a recombinant MVSchw virus expressing an HIV-1(89.6) gp140 glycoprotein whose hyper variable V1, V2 and V3 loops were deleted (DeltaV1V2V3gp140), induces broadly neutralizing antibodies against HIV-1 primary isolates. These results show that the MVSchw pediatric vaccination vector induces efficient cellular and humoral HIV-specific immune responses.
    Vaccine 09/2005; 23(36):4463-72. DOI:10.1016/j.vaccine.2005.04.024 · 3.49 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: CD8(+) T lymphocytes are thought to play an important role in the control of acute and chronic human immunodeficiency virus infections. However, there is a significant delay between infection and the first observed increase in virus-specific CD8(+) T-cell numbers. Prior to this time, viral kinetics are not significantly different between controls and vaccinees. Surprisingly, higher initial virus-specific CD8(+) T-cell numbers lead to a longer delay prior to initial CD8(+) T-cell expansion, and slower CD8(+) T-cell increases. Nevertheless, higher initial CD8(+) T-cell numbers were associated with reduced peak and chronic viral loads and reduced CD4(+) T-cell depletion.
    Journal of Virology 09/2005; 79(15):10059-62. DOI:10.1128/JVI.79.15.10059-10062.2005 · 4.65 Impact Factor
Show more